Baricitinib is Used for treating severe alopecia areata, COVID-19 in hospitalized adults requiring supplemental oxygen, ventilation, or ECMO, and rheumatoid arthritis. It was first introduced by Eli Lilly And Co in its drug Olumiant on May 31, 2018. 3 different companies have introduced drugs containing Baricitinib.
Baricitinib Patents
Given below is the list of patents protecting Baricitinib, along
with the drug name that holds that patent and the company name owning that
drug.
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on
Baricitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Several generic applications have been filed for Baricitinib. The first generic version for Baricitinib was by Aurobindo Pharma Ltd and was approved on Jul 22, 2024. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Aug 8, 2025.
Given below is the list of companies who have filed for
Baricitinib generic, along with the locations of their manufacturing plants worldwide.
